These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36929120)

  • 1. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
    Fitzgerald T; Zhdanava M; Pilon D; Shah A; Hilts A; Lefebvre P; Feldman SR
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):1053-1068. PubMed ID: 36929120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of persistence and remission with guselkumab
    Zhdanava M; Fitzgerald T; Pilon D; Teneralli RE; Shah A; Diaz L; Lefebvre P; Feldman SR
    J Dermatolog Treat; 2024 Dec; 35(1):2349658. PubMed ID: 38747375
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.
    Li Y; Lu JJ; Zhong XY; Yu YY; Yu N; Wang Y; Yi XM; Ding YF; Shi YL
    Clin Cosmet Investig Dermatol; 2022; 15():2245-2252. PubMed ID: 36304759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
    Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
    J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.
    Fitzgerald T; Near AM; Kim H; Teeple A; Olurinde M; Rowland K
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):741-752. PubMed ID: 35212934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
    Fitzgerald T; Zhdanava M; Pilon D; Shah A; Lefebvre P; Feldman SR
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2917-2923. PubMed ID: 37752408
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.
    Bagel J; Glick B; Wu JJ; Chopra I; Song X; Brouillette M; Mendelsohn A; Rozzo S; Han G
    J Med Econ; 2021; 24(1):782-791. PubMed ID: 34107834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA.
    Pilon D; Fitzgerald T; Zhdanava M; Teeple A; Morrison L; Shah A; Lefebvre P
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):971-987. PubMed ID: 35305255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    Patient Prefer Adherence; 2020; 14():517-527. PubMed ID: 32210539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
    Armstrong A; Xia Q; John AR; Patel V; Seigel L
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
    Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.